Asterias Biotherapeutics Inc diskutieren
Asterias Biotherapeutics Inc
Name: Asterias / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
-
-
Stier
a +
(Zielkurs erreicht)
Healthcare | Biotechnologie | USA
hat $
(Vom Mitglied beendet)
Affe sagt kaufen
(Vom Mitglied beendet)
SecteurRecherche biotechnologique et médicale Agenda 12/11 Publication de résultats
Operates as a biotechnology company
Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine.
The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology.
Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer.
The company was founded on September 24, 2012 and is headquartered in Fremont, CA.
Asterias Biotherapeutics, Inc. is a clinical-stage biotechnology company, which is focused on developing and commercializing novel therapies in the emerging fields of cell therapy and regenerative medicine.
The company is also focused on developing therapies to treat conditions with unmet medical needs and inadequate available therapies, with an initial focus on the therapeutic areas of oncology and neurology.
Its product candidates include AST-OPC1, trial for spinal cord injuries; AST-VAC1, a patient specific cancer immunotherapy focused on acute myeloid leukemia; and AST-VAC2, a non-patient-specific cancer immunotherapy for non-small cell lung cancer.
The company was founded on September 24, 2012 and is headquartered in Fremont, CA.
Nombre d'employés
: 31 personnes.
(Vom Mitglied beendet)
Neueste Beiträge
reedtomorrow in Vista Gold Corp. diskutieren